These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 19589894

  • 1. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.
    Bingham CO, Smugar SS, Wang H, Tershakovec AM.
    Rheumatology (Oxford); 2009 Sep; 48(9):1122-7. PubMed ID: 19589894
    [Abstract] [Full Text] [Related]

  • 2. Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis.
    Bingham CO, Bird SR, Smugar SS, Xu X, Tershakovec AM.
    Osteoarthritis Cartilage; 2008 Nov; 16(11):1289-93. PubMed ID: 18514551
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM.
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [Abstract] [Full Text] [Related]

  • 4. Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo.
    Bingham CO, Smugar SS, Wang H, Peloso PM, Gammaitoni A.
    Pain Med; 2011 Mar; 12(3):352-61. PubMed ID: 21332932
    [Abstract] [Full Text] [Related]

  • 5. Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial.
    Yoo MC, Yoo WH, Kang SB, Park YW, Kim SS, Moon KH, Song YW, Min BW, Cho YJ, Moon SH, Bin SI, Baek HJ, Shim SC, Lee SW, Yoo DH, Mehta A, Skuban A, Cukrow DM, Vandormael K, Yan L.
    Curr Med Res Opin; 2014 Dec; 30(12):2399-408. PubMed ID: 25133963
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S.
    Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS.
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [Abstract] [Full Text] [Related]

  • 8. The use of etoricoxib and celecoxib for pain prevention after periodontal surgery: a double-masked, parallel-group, placebo-controlled, randomized clinical trial.
    Steffens JP, Santos FA, Pilatti GL.
    J Periodontol; 2011 Sep; 82(9):1238-44. PubMed ID: 21235334
    [Abstract] [Full Text] [Related]

  • 9. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
    Fleischmann R, Sheldon E, Maldonado-Cocco J, Dutta D, Yu S, Sloan VS.
    Clin Rheumatol; 2006 Feb; 25(1):42-53. PubMed ID: 16132165
    [Abstract] [Full Text] [Related]

  • 10. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice.
    Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H.
    Ann Rheum Dis; 2010 Feb; 69(2):374-9. PubMed ID: 19364730
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.
    Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, Castro R, Sanchez M, Detora LM, Ng J.
    Curr Med Res Opin; 2002 Feb; 18(2):49-58. PubMed ID: 12017209
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ, Weaver AL, Polis AB, Petruschke RA, Geba GP, VACT-1 and VACT-2 (Protocols 106 and 150) Study Groups.
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [Abstract] [Full Text] [Related]

  • 13. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study.
    Emery P, Koncz T, Pan S, Lowry S.
    Clin Ther; 2008 Jan; 30(1):70-83. PubMed ID: 18343244
    [Abstract] [Full Text] [Related]

  • 14. Treatment of osteoarthritis with continuous versus intermittent celecoxib.
    Strand V, Simon LS, Dougados M, Sands GH, Bhadra P, Breazna A, Immitt J.
    J Rheumatol; 2011 Dec; 38(12):2625-34. PubMed ID: 22045833
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
    Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, Litschig S, Sloan VS.
    Curr Med Res Opin; 2005 Apr; 21(4):517-26. PubMed ID: 15899100
    [Abstract] [Full Text] [Related]

  • 16. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis.
    Zacher J, Feldman D, Gerli R, Scott D, Hou SM, Uebelhart D, Rodger IW, Ozturk ZE, etoricoxib OA study group.
    Curr Med Res Opin; 2003 Apr; 19(8):725-36. PubMed ID: 14687444
    [Abstract] [Full Text] [Related]

  • 17. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
    Smugar SS, Schnitzer TJ, Weaver AL, Rubin BR, Polis AB, Tershakovec AM.
    Curr Med Res Opin; 2006 Jul; 22(7):1353-67. PubMed ID: 16834834
    [Abstract] [Full Text] [Related]

  • 18. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [Abstract] [Full Text] [Related]

  • 19. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis.
    Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, Wolfe F, Gibofsky A, Simon L, Zlotnick S, Fort JG.
    Ann Rheum Dis; 2004 Aug; 63(8):931-9. PubMed ID: 15082468
    [Abstract] [Full Text] [Related]

  • 20. A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip.
    Luyten FP, Geusens P, Malaise M, De Clerck L, Westhovens R, Raeman F, Vander Mijnsbrugge D, Mathy L, Hauzeur JP, De Keyser F, Van den Bosch F.
    Ann Rheum Dis; 2007 Jan; 66(1):99-106. PubMed ID: 16815864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.